Early research (Phase 1)Ended earlyNCT01611675What this trial is testingLeflunomide+Vemurafenib in V600 Mutant Met. MelanomaWho this might be right forMelanoma Massachusetts General Hospital 3
Testing effectiveness (Phase 2)Ended earlyNCT01616199What this trial is testingStudy of PX-866 and Vemurafenib in Patients With Advanced MelanomaWho this might be right forAdvanced BRAF-mutant Cancers Cascadian Therapeutics Inc. 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04417621What this trial is testingStudy of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaWho this might be right forMelanoma Novartis Pharmaceuticals 134
Early research (Phase 1)Study completedNCT03864042What this trial is testingPharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsMetastatic Melanoma Pfizer 56
Early research (Phase 1)Ended earlyNCT01940809What this trial is testingIpilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryWho this might be right forBRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)UnknownNCT04720768What this trial is testingEncorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATEWho this might be right forMelanomaMetastasis Peter MacCallum Cancer Centre, Australia 78
Early research (Phase 1)Looking for participantsNCT05538130What this trial is testingLearn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsWho this might be right forMelanomaGliomaThyroid Cancer+10 more Pfizer 124
Early research (Phase 1)Study completedNCT05668585What this trial is testingCharacterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid TumorsWho this might be right forSolid TumorsMelanomaNSCLC+2 more C4 Therapeutics, Inc. 89
Testing effectiveness (Phase 2)WithdrawnNCT03005639What this trial is testingML29255 Neoadjuvant Vemurafenib and Cobimetinib MelanomaWho this might be right forStage IIIB-C Melanoma Inova Health Care Services
Testing effectiveness (Phase 2)Ended earlyNCT01721603What this trial is testingDabrafenib and Trametinib With Radiosurgery in Melanoma Brain MetsWho this might be right forBRAFV600E Melanoma Patients University of California, San Francisco 2
Early research (Phase 1)Ended earlyNCT02097225What this trial is testingOnalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryWho this might be right forBRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Study completedNCT01902173What this trial is testingUprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerWho this might be right forHematopoietic and Lymphoid Cell NeoplasmLocally Advanced Malignant Solid NeoplasmLocally Advanced Melanoma+6 more National Cancer Institute (NCI) 27
Testing effectiveness (Phase 2)Study completedNCT02296996What this trial is testingDabrafenib and Trametinib for BRAF-inhibitor Pretreated PatientsWho this might be right forMalignant Melanoma Universitair Ziekenhuis Brussel 25
Testing effectiveness (Phase 2)Study completedNCT01512251What this trial is testingBKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced MelanomaWho this might be right forBRAF Mutant Metastatic Melanoma University of California, San Francisco 8
Early research (Phase 1)Study completedNCT01436656What this trial is testingA Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaWho this might be right forMelanoma and Metastatic Colorectal Cancer Pfizer 107
Testing effectiveness (Phase 2)Study completedNCT02902042What this trial is testingEncorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaWho this might be right forMalignant Melanoma Prof. Dr. med. Dirk Schadendorf 16
Testing effectiveness (Phase 2)Ended earlyNCT04655157What this trial is testingSafety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaWho this might be right forMelanoma Jason J. Luke, MD 2
Early research (Phase 1)Ended earlyNCT05501912What this trial is testingABM-1310 in Patients With BRAF V600-Mutant Advanced Solid TumorsWho this might be right forAdvanced Solid TumorBRAF V600 Mutation ABM Therapeutics Shanghai Company Limited 20
Early research (Phase 1)Study completedNCT05003622What this trial is testingPhase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid TumorsWho this might be right forBRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma Pierre Fabre Medicament 3
Early research (Phase 1)Ended earlyNCT03272464What this trial is testingINCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.Who this might be right forMelanoma Massachusetts General Hospital 1